Mesenchymal stem cell therapy in equine musculoskeletal disease: scientific fact or clinical fiction?
Authors: Taylor S E, Smith R K W, Clegg P D
Journal: Equine veterinary journal
Summary
# Editorial Summary: Mesenchymal stem cell therapy in equine musculoskeletal disease Mesenchymal stem cell (MSC) therapy holds considerable promise for treating musculoskeletal injuries in horses, particularly superficial digital flexor tendonitis—a condition so prevalent and functionally limiting that equine practice has become a proving ground for tendon regeneration research. Taylor, Smith and Clegg conducted a comprehensive review of the state of MSC science and its clinical applications, examining laboratory protocols for MSC isolation and expansion in horses alongside theoretical mechanisms of tissue regeneration. Whilst laboratory techniques for harvesting equine MSCs are now established and the scientific rationale is sound, the authors found that clinical translation remains in its infancy; the field is demonstrably young and substantial further research is required before MSC therapy can be reliably deployed as a highly efficient treatment. For practitioners considering this technology, the key message is one of measured optimism: the regenerative potential justifies continued investigation, but current evidence and practical limitations demand realistic communication with clients and careful patient selection until protocols are more rigorously validated. Understanding both the genuine promise and genuine constraints of the technology is essential to maintaining professional credibility whilst the science matures.
Read the full abstract on PubMed
Practical Takeaways
- •MSC therapy for equine tendon disease shows promise but remains largely experimental; clinicians should maintain realistic expectations and inform clients that this is not yet a proven standard treatment
- •The significant prevalence of superficial digital flexor tendonitis in horses means this species is driving research forward, but benefits may take years to materialize into clinical practice
- •Be cautious of claims of 'functional tissue engineering' success until peer-reviewed evidence demonstrates superior outcomes compared to conventional rehabilitation protocols
Key Findings
- •MSC isolation from equine tissues is now well established and feasible for clinical application
- •Superficial digital flexor tendonitis prevalence in horses has positioned equine veterinary science at the forefront of tendon regeneration research
- •Despite significant laboratory progress, the field remains relatively young and requires considerable additional time and effort to develop MSC therapy into highly efficient clinical treatments
- •Current understanding must balance the technology's regenerative potential against acknowledged limitations in tissue engineering efficiency